Lu 177 vs chemo/docetaxel: Lu 177 vs... - Advanced Prostate...

Advanced Prostate Cancer

20,784 members25,890 posts

Lu 177 vs chemo/docetaxel

Runner4000 profile image
33 Replies

Lu 177 vs chemo/docetaxel.

What are the requirements to be able to be on Lu 177 in the U.S? Are they different in Germany? In Australia? Has anyone seen any studies--from the U.S. or other countries--comparing the effectiveness of Lu 177 to chemo/docetaxel? I am on Lupron, which I understand at some point won't continue to hold down my PSA. Then I'll have to exercise other options--such as Lu 177 or chemo.

Written by
Runner4000 profile image
Runner4000
To view profiles and participate in discussions please or .
Read more about...
33 Replies
RyderLake2 profile image
RyderLake2

Hello,

Normal procedure is to go to on one of the second tier drugs like Xtandi (enzalutamide) or Zytiga (abiraterone acetate) and then move onto Lutetium 177 or chemo when those drugs fail. Some of the German clinics like you to be on Xtandi prior to going on Lutetium. It increases the effectiveness of the Lutetium. Hope that helps!

Claud68 profile image
Claud68

We found a radio oncologist in Vienna, Austria who accepted to administer the Lu177 treatment instead of any ADT or RT after the biochemical recurrence following the RP. The Ga68-PSMA petscan detected 6 mets in lymphnods. After three Lu177 shots the PSA dropped from 4.4 to 0.34 and maybe it will continue to fall. We'll check in March or April if all the mets disappeared and if there are no news ones.

The most ROs in Germany accept only castration resistant patients after ADT.

Runner4000 profile image
Runner4000 in reply to Claud68

Thanks everyone for your responses to date.

dustydog profile image
dustydog in reply to Claud68

Can you give me the name of the radio oncologist in Vienna? I am looking for such a person here in Vienna.

Claud68 profile image
Claud68 in reply to dustydog

My husband was treated in Vienna/ Austria by Prof. Markus Hartenbach even he was totally hormone naive.

On the website minute-medical.com you will see a lot of information. He speeks also English very well and his phone number is +43 677 625 45515.

We paid 14000€ for each treatment and before, my husband had a Ga68-PSMA petscan in Vienna too, it was 2250€. I know that the main hospital in Vienna, AKH, treats some patients after ADT and/ or Chemotherapy with Lu177. I think that it is free if you are resident in Austria?

Tall_Allen profile image
Tall_Allen

The open US trials in SF and NY require chemo before Lu-177-PSMA. There are no comparative effectiveness studies.

Runner4000 profile image
Runner4000 in reply to Tall_Allen

Tall_Allen, do you know what the situation is outside of the US in terms of prerequisites for Lu-177?

Tall_Allen profile image
Tall_Allen in reply to Runner4000

In Germany, India and South Africa, you can get Lu-177-PSMA outside of clinical trials.

Runner4000 profile image
Runner4000 in reply to Tall_Allen

Thanks.

JP63 profile image
JP63 in reply to Runner4000

You can also get it from Australia outside a trial.

Redgold profile image
Redgold in reply to Tall_Allen

I read Lu177 is more effective before chemo. mdpi.com/1424-8247/15/10/12...

Tall_Allen profile image
Tall_Allen in reply to Redgold

Many misunderstood that, but there is really no such evidence yet.

AlanLawrenson profile image
AlanLawrenson

As you can in Australia. About US$7000 per treatment. My brother had 4 cycles and to an extent took his eye of the ball at a critical time. His PSA went from 1 to 105 in 8 weeks, more than doubled again in two further weeks and then doubled again. Sadly, he died 4 weeks ago. When he started having pelvic pain, he should have started docetaxel immediately. He might still be alive today, if he had done so.

However, it is possible that, in hindsight, his Stage 4 cancer morphed in neuroendocrine PC, which is extreme aggressive form of CRPC. The docetaxel would then not have helped him.

Go to theranostics.com.au for more details.

pakb profile image
pakb

Are you currently only doing Lupron? I believe more the standard now, depending on diagnosis details, is ADT plus either Zytiga or Chemo. As per current studies. Not waiting for lupron to stop working before adding chemo or Zytiga. Not sure if LU 77 has the same studies.

Canoetripper profile image
Canoetripper

UW Madison is currently doing a Clinical trial UW 18028 It is a phase I/ll dose escalation study of safety tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of 177LU-PSMA radio-ligand therapy in patients with prostate specific membrane antigen PSMA positive (68Ga-PSMA-R2) progressive metastatic castration resistant prostate cancer. It is open and there are two phases. The first phase requires weekly blood work at UW. The second phase requires blood work every 2 weeks at UW. Treatment are every 6 weeks. My husband had his first infusion yesterday and he has to follow some strict restrictions for 3 to 7 days due to radioactivity.

You can find this study by using Google put in UW clinical trials prostate and look for the number.

Bangkok profile image
Bangkok in reply to Canoetripper

Read my posts regarding radio ligand. Three treatments in Bangkok and I'm in remission with no Mets.

Canoetripper profile image
Canoetripper

The study at UW requires previous systematic treatment. UW18028. Where this treatment will fit in the treatment sequence is not yet known. I thought I read a study that suggested better results if the person did not have chemo first. This treatment in the US is still available only in clinical trials

Fairwind profile image
Fairwind

At the moment, Lu-177 is only available through a limited number of clinical trials in only one location in the U.S...It is available in Germany if you can afford it..At the moment, it's a last resort treatment and it does not provide a cure, If you are lucky, it can extend mortality significantly..This is serious radiation treatment and it can have serious side-effects..

Runner4000 profile image
Runner4000 in reply to Fairwind

Thanks for the helpful additional responses.

Bangkok profile image
Bangkok in reply to Fairwind

No side effects. I continued running my normal daily 5k with my wife two days after each (painless) treatment. I'm 73.

j-o-h-n profile image
j-o-h-n

Can you give us more info about yourself? age, location, treatment center(s),doctor's name(s). All info is voluntary but it helps us help you and helps us too. Thank you!!!

Good Luck, Good Health and Good Humor.

j-o-h-n Thursday 02/20/2020 6:25 PM EST

Bangkok profile image
Bangkok in reply to j-o-h-n

Read my previous posts re: radioligand.

j-o-h-n profile image
j-o-h-n in reply to Bangkok

Thank you for your response which referred to your bio in your home page. Best wishes to you and your wife....

Good Luck, Good Health and Good Humor.

j-o-h-n Saturday 10/24/2020 12:36 PM DST

j-o-h-n profile image
j-o-h-n in reply to Bangkok

If you missed this post, you may be interested in this post by "pjoshea13

" 3 months ago.

PSMA expression & Survival in advanced PCa treated by 177 Lu-PSMA-617 Radioligand Therapy

pjoshea13•

3 months ago•5 Replies

Interesting new German study below [1].

***

The terms used below are:

PSMAaverage ... lowPSMAaverage ... highPSMAaverage

PSAmin ... lowPSMAmin ... highPSMAmin

PSMAmax

***

"PSMAaverage was a significant prognosticator of overall survival in contrast to PSMAmax (HR: 0.959 ... vs. HR: 0.992 ...).

"Patients with low average PSMA expression (lowPSMAaverage) had significantly shorter survival compared to those with high average expression (highPSMAaverage) (5.3 vs. 15.1 months ... HR: 3.738 ...).

"Patients with low PSMA expressing metastases (lowPSMAmin) had shorter survival compared to those without a low PSMA expressing metastasis (highPSMAmin) ... 7.9 months vs. 21.3; HR: 4.303, ...).

"Patients that were classified as highPSMAaverage but with lowPSMAmin had an intermediate overall survival (11.4 months; longer compared to lowPSMAaverage, 5.3 months ... but shorter compared to highPSMAmin, 21.3 months ...)."

-Patrick

[For more detail, send me a private message.]

[1] pubmed.ncbi.nlm.nih.gov/326...

Theranostics

. 2020 Jun 19;10(17):7812-7820. doi: 10.7150/thno.47251. eCollection 2020.

Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving 177 Lu-PSMA-617 Radioligand Therapy

Robert Seifert 1 2 3 4 , Konstantin Seitzer 1 4 5 , Ken Herrmann 2 3 4 , Katharina Kessel 1 , Michael Schäfers 1 4 , Jens Kleesiek 3 6 , Matthias Weckesser 1 4 , Martin Boegemann 4 5 , Kambiz Rahbar 1 4

Affiliations collapse

Affiliations

1 Department of Nuclear Medicine, University Hospital Münster, Münster, Germany.

2 Department of Nuclear Medicine, University Hospital Essen, Essen, Germany.

3 German Cancer Consortium (DKTK).

4 West German Cancer Center.

5 Department of Urology, University Hospital Münster, Münster, Germany.

6 Division of Radiology, German Cancer Research Center, Heidelberg, Germany.

PMID: 32685021 PMCID: PMC7359095 DOI: 10.7150/thno.47251

Abstract

Rationale: PSMA-PET-CT enables measuring molecular expression of prostate-specific membrane antigen (PSMA) in vivo, which is the target molecule of 177Lu-PSMA-617 (Lu-PSMA) therapy. However, the correlation of PSMA expression and overall survival (OS) in patients treated with Lu-PSMA therapy is currently unclear; especially with regard to coexistence of high and low PSMA expressing metastases. To this end, this retrospective single arm study elucidates the correlation of PSMA expression and overall survival in patients treated with Lu-PSMA therapy. Additionally, PET based criteria to define low PSMA expression were explored. Methods: Eighty-five patients referred to Lu-PSMA therapy were included in the analysis. Pretherapeutic 68Ga-PSMA-PET-CT scans were available for all patients. SUVmax of the highest PSMA expressing metastasis (PSMAmax), SUVmax of the lowest PSMA expressing metastasis (PSMAmin), and average SUVmax of all metastases (PSMAaverage) amongst other PET parameters were measured for each patient. A log-rank cutoff-finder was used to determine low (lowPSMAaverage) and high (highPSMAaverage) average PSMA expression as well as low (lowPSMAmin) and high (highPSMAmin) minimal PSMA expression. Results: PSMAaverage was a significant prognosticator of overall survival in contrast to PSMAmax (HR: 0.959; p = 0.047 vs. HR: 0.992; p = 0.231). Optimal log rank cut-offs were: PSMAaverage = 14.3; PSMAmin = 10.2. Patients with low average PSMA expression (lowPSMAaverage) had significantly shorter survival compared to those with high average expression (highPSMAaverage) (5.3 vs. 15.1 months; p < 0.001; HR: 3.738, 95%CI = 1.953-7.154; p < 0.001). Patients with low PSMA expressing metastases (lowPSMAmin) had shorter survival compared to those without a low PSMA expressing metastasis (highPSMAmin) (p = 0.003; 7.9 months vs. 21.3; HR: 4.303, 95%CI = 1.521-12.178; p = 0.006). Patients that were classified as highPSMAaverage but with lowPSMAmin had an intermediate overall survival (11.4 months; longer compared to lowPSMAaverage, 5.3 months, p = 0.002; but shorter compared to highPSMAmin, 21.3 months, p = 0.02). Conclusion: Low average PSMA expression is a negative prognosticator of overall survival. Absence of low PSMA expressing metastases is associated with best overall survival and the maximum PSMA expression seems not suited to prognosticate overall survival. Low PSMA expression might therefore be a negative prognosticator for the outcome of patients treated with Lu-PSMA therapy. Future studies are warranted to elucidate the degree of low PSMA expression tolerable for Lu-PSMA therapy.

Keywords: PSMA PET; PSMA radioligand therapy; prognosticator; prostate cancer.

© The author(s).

Related Tags

cancer and tumoursbladder cancer

Jump to replies

Featured Content

Good Luck, Good Health and Good Humor.

j-o-h-n Saturday 10/24/2020 1:31 PM DST

Bangkok profile image
Bangkok in reply to j-o-h-n

That's all Greek to me John. I went in cold turkey no previous meddling around. My Thai Oncologist said he was interested in my case as I was unusual in that most of the radio ligand patients were end stage. My aerobic fitness and the fact that I had just returned from a cycling trip in Vietnam where we covered from 80-110 km per day for 10 days made him interested in my case.

j-o-h-n profile image
j-o-h-n in reply to Bangkok

I speak Greek, that's why I got it............ Good deal that you worked out since you were 20 years old. Definitely an asset in fighting 'THE BEAST"...... Keep on Keeping on.

Good Luck, Good Health and Good Humor.

j-o-h-n Sunday 10/25/2020 11:32 AM DST

paige20180 profile image
paige20180

We are leaving for Delhi, India tomorrow and being treated by Dr. Shen at Fortis Memorial Research Institute. Cost is $5,500 US. My husband is still hormone sensitive. He was on Lupron for 14 months just prior and 1 year after radiation to his pelvis.

jdm3 profile image
jdm3 in reply to paige20180

Great that you found a place to go with a good reputation that you can get to. Safe travels and hope all goes well with the treatment!🙏

Keep us posted.

Bangkok profile image
Bangkok in reply to paige20180

India has over 200,000 Covid cases per day. Take all precautions.

Bangkok profile image
Bangkok

Read my posts. I think it will be informative for you.

Hope59 profile image
Hope59 in reply to Bangkok

I read your post and the radiation sounds like it’s working great. Congrats! I was just wondering what your PSA was before treatment. You posted several different numbers (990, 9.8)?

Bangkok profile image
Bangkok

It was 998. It seems there are different interpretations. It was really high and my initial PETScan showed I was lit up like a Christmas 🎄. Nothing showing now. I met someone who had their treatments in Germany and the protocol was much different. They had to stay in hospital for 2 days post treatments and no more than one treatment every two months. In Bangkok I was in and out in a little over three hours and one month between treatments.

paige20180 profile image
paige20180

Hi Runner4000.

We are currently in New Delhi for round two of LU177. We are seeing Dr. Sen at Fortis Memorial. My husband has never had chemo and he is hormone sensitive.

He was taken off Lupron for a year and developed metastasis. His doctors wanted to see if radiation to the prostate bed had worked. Charlie was on Lupron for 1 year after his prostate bed was radiated in 5/18. Lupron wore off 6/19. The lesions that resulted from ending Lupron were treated with Radiation. His hip metastasis was eliminated but metastasis on his spine did not respond long term to radiation.

Our doctor recommended LU177. PSA went from 4 to .24 six weeks after first treatment. Casodex was started 1 week before the .24. We can not be entirely sure if the reduction was from LU177 or Casodex. PSA one month after LU177 was about the same. We had a long delay trying to get an Eligard shot so Casodex was used a week prior to the .24 PSA.

The PSMA done yesterday shows a 76% reduction in 4 lesions after 8 weeks. To be clear, the treatments that could have caused this reduction are Lutecium given 8 weeks ago, Casodex taken for 12 days week 4-6. Eligard injection week 5.

I was in the room for Charlie's second treatment and slept next to him as normal 6 hours after treatment. Much different than I hear they do things in Germany.

I feel like Charlie is a bit of an experiment doing Lutecium early in his treatment and the results will play out. All the best to you!

You may also like...

Lu-177 as SOC vs Clinical Trial

cabazitazel/carboplatin chemo treatment, we're looking at options and working on Lu-177. I'm...

Starting docetaxel and LU-177 any feedback welcome from others same situation

I have stage 4 had chemo docetaxel bicudimate and then xtandi which quit working cancer spreading...

LU 177 better if you did not take any ADT or CHEMO prior

over here, does someone got LU 177 prior to any other treatment (ADT / CHEMO ) and see better...

Lu-177 as of June 21 2019

I've got other paperwork under review at U Heidelberg So, the questions are: do you know other...

Pluvicto / Lu-177 - Do it now or later?

limited remaining SOC options: another round of the dreaded chemo like docetaxel or Lu-177 /...